Product Description
Capsaicin is a capsaicinoid. It has a role as a non-narcotic analgesic, a voltage-gated sodium channel blocker and a TRPV1 agonist. Capsaicin is a chili pepper extract with analgesic properties. Capsaicin is a neuropeptide releasing agent selective for primary sensory peripheral neurons. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Capsaicin)
Mechanisms of Action: TRPV1 Agonist, GABA Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical, Transdermal
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: NeurogesX
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, France, Netherlands, Poland, Spain, Sweden, United Kingdom, United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Neuropathic Pain
Phase 2: Animal Hypersensitivity|Asthma|Chronic Cough|Chronic Pain|Environmental Hypersensitivity|Evans Syndrome|Fish Hypersensitivity|Food Hypersensitivity|Labor Pain
Phase 1: Healthy Volunteers|Pain Unspecified|Peripheral Nervous System Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCI-2024-10413 | P1 |
Not yet recruiting |
Peripheral Nervous System Diseases |
2027-11-30 |
50% |
2025-08-07 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments |
| MK-0000-420 | P1 |
Completed |
Pain Unspecified|Healthy Volunteers |
2023-12-15 |
2025-02-06 |
Primary Endpoints|Treatments |
|
| NCT04125563 | P2 |
Active, not recruiting |
Chronic Pain|Chronic Cough|Environmental Hypersensitivity|Neuropathic Pain|Fish Hypersensitivity|Asthma|Food Hypersensitivity|Labor Pain|Evans Syndrome|Animal Hypersensitivity |
2025-12-30 |
2024-11-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
| Acute Hernia Study | P2 |
Completed |
Unknown |
2025-01-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| AV001 | P3 |
Active, not recruiting |
Neuropathic Pain |
2025-08-30 |
2025-05-02 |
Treatments |
|
| RISE | P3 |
Completed |
Neuropathic Pain |
2025-03-07 |
21% |
2025-09-03 |
Primary Endpoints|Study Completion Date |
| 2021-001409-64 | P3 |
Active, not recruiting |
Neuropathic Pain |
2024-01-10 |
2025-05-06 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/25/2025 |
News Article |
Buying Guide -Instant female arousal pills over the counter 2025 By OhYes |
|
09/18/2025 |
News Article |
Buying Guide to the Top & Most Effective Fat Burner for Men- 10 Effective Men's Fat Burning Supplements- Wolfsan Brand launch 2025 |
|
09/04/2025 |
News Article |
Automatic Trap Company Offers a Smart Defense to Avoid Up to $15,000 in Vehicle Repairs from Rodent Damage with Humane and Non-Toxic Self-Resetting Trap Solutions |
|
07/16/2025 |
News Article |
Become an Arkay Zero Proof Distributor - No Liquor License Required, Full Flavor Guaranteed |